

eTable 1. Characteristics and laboratory outcome of reported psoriatic patients with chronic HCV infection treated with anti-TNF- α agents

Footnotes. Abbreviations: N, number of patients; NA, not available; PsA, psoriatic arthritis; Eta, etanercept; Ada, adalimumab; Infx, infliximab. Symbols: §, in the

Authors Ref. §	N	Type of psoriasis	PsA	Anti-TNF- α agents	Duration of therapy (months)	HCV genotype	Pretreatmen t liver fibrosis stage ¶	Trans aminases outcome	HCV viral load outcome
Khanna ¹	1	NA	+	Eta	NA	NA	NA	NA	NA
Magliocco ²	3	Plaque	+/-/+	Eta/Eta/Eta	7/5/3	NA	F1/F1/F1	=/=	↓/↓/NA
Cecchi ³	1	Plaque	-	Eta	12	1	F0	=	=
De Simone ⁴	2	Plaque	+/-	Eta/Eta	12/12	4/1	F1/NA	=/	↓/↓
Pitarch ⁵	1	Plaque	+	Ada	5	NA	NA	=/	NA
Rokhsar ⁶	1	Plaque	+	Eta	12	NA	F3	NA	=
Aslanidis ⁷	1	NA	+	Infx (-) Ada	6(-)6	1	F1	=(-)NA	↓(-)NA
Linardaki ⁸	1	Plaque	+	Eta	24	1	F2	=	=
Alcaide ⁹	1	Plaque	-	Eta	6	1	NA	=	=
Cassano ¹⁰	1	Plaque	-	Eta	6	NA	NA	=	=
Cavazzana ¹¹	1	NA	+	Eta	14	NA	NA	=	=
Collazo ¹²	1	Plaque	-	Eta	3	NA	NA	=	NA
Piccolo ¹³	1	Plaque	-	Eta	11	1	NA	↓	↓
Behnam ¹⁴	1	Plaque	-	Eta	20	NA	F3	↓	↓
Prignano ¹⁵	1	Plaque	-	Eta	6	1	F0	NA	=
Ricchetta ¹⁶	1	Erythro dermic	-	Ada	1	NA	NA	NA	NA
Ventura ¹⁷	2	Plaque	NA/+	Eta/Eta	6/18	3/1	NA	=/	↑/↓
Di Lernia ¹⁸	1	Plaque	-	Infx	10	NA	NA	=	=
Gandhi ¹⁹	1	Plaque	NA	Eta	12	NA	F3	↓	↓
Garavaglia ²⁰	5	NA	+/-/ -/-	Eta/Eta/Eta/Eta/Eta	24/14/10/8/22	NA	NA	↓/=↓/↑	↓/=/=↑
Paradisi ²¹	2	Plaque	+/-	Eta/Eta	12/12	4/1	F2/F1^	=/	=/
Mederacke ²²	1	NA	+	Eta	6	3	F3	NA	↓
Prignano ²³	6	Plaque	NA	Eta/Eta/Eta/Ada/Ada/Eta(-)Ada	Mean 11	2/2/2/1/1/1	NA	=/==/=/(→)=	=/==/=/(→)=
Zanni ²⁴	3	Plaque	+/-/+	Eta/Eta/Eta	6/6/6	1/2/2	F4/NA/NA	↑/=	=/=/
Collazo ²⁵	1	plaque 18 plaque	-	Eta	5	NA	F4	=	↓
Navarro ²⁶	20	1 palmoplantar 1 erythrodermic	-	13 Eta/ 1 Ada/ 3Eta(-)Ada/ 1 Eta(-) Infx	See references	NA	1 patients with alcoholic F4	See references	See references

reports with case series, patient data are presented in different columns accordingly; ¥, fibrosis was graded from F0 to F4 on the basis of the liver histology reported in the given literature (F0, no fibrosis; F1, mild; F2, moderate; F3, severe; F4, cirrhosis); ^, a post-treatment liver biopsy was available in these patients; =, no change; ↓, decreased; ↑, increased; (→), switch.

eReferences

1. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. *J Dermatol Treat.* 2003;14(4):229-232.
2. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases. *J Am Acad Dermatol.* 2004;51(4):580-584.
3. Cecchi R, Bartoli L. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). *Dermatol Online J.* 2006;12(7):4.
4. De Simone C, Paradisi A, Capizzi R, et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. *J Am Acad Dermatol.* 2006;54(6):1102-1104.
5. Pitarch G, Sanchez-Carazo JL, Mahiques L, et al. Treatment of psoriasis with adalimumab. *Clin Exp Dermatol.* 2007;32(1):18-22.
6. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. *J Am Acad Dermatol.* 2006;54(2):361-362.
7. Aslanidis S, Vassiliadis T, Pyrpasopoulou A, et al. Inhibition of TNF α does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. *Clin Rheumatol.* 2007;26(2):261-264.
8. Linardaki G, Katsarou O, Ioannidou P, et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. *J Rheumatol.* 2007;34(6):1353-1355.
9. Alcaide AJ, Barrera MV, Habicheyn S, et al. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection. *J Eur Acad Dermatol Venereol.* 2008;22(12):1514-1516.
10. Cassano N, Vena GA. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. *Int J dermatol.* 2008;47(9):980-981.
11. Cavazzana I, Ceribelli A, Cattaneo R, et al. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. *Autoimmun Rev.* 2008;8(2):104-106.
12. Collazo MH, González JR, Torres EA. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. *P R Health Sci J.* 2008;27(4):346-347.
13. Piccolo D, Di Cesare A, Farnoli MC, et al. Effective control of psoriasis by etanercept in a patient with HCV-related diseases. *Eur J Dermatol.* 2008;18(4):459-460.

14. Behnam SE, Hindiyeh R, Fife DJ, et al. Etanercept as prophylactic psoriatic therapy before interferon- α and ribavirin treatment for active hepatitis C infection. *Clin Exp Dermatol.* 2010;35(4):397-398.
15. Prignano F, Zanieri F, Milani S, et al. Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. *Dermatol Ther.* 2009;22(4):386-390.
16. Richetta AG, Maiani E, Carlomagno V, et al. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. *Dermatol Ther.* 2009;22 (Suppl 1):S16-18.
17. Ventura F, Gomes J, Duarte Mda L, et al. Efficacy and safety of etanercept in patients with psoriasis and hepatitis C. *Eur J Dermatol.* 2010;20(6):808-809.
18. Di Lernia V, Guareschi E. Successful treatment of hand and foot psoriasis with infliximab. *Dermatol Online J.* 2010;16(7):8.
19. Gandhi RK, Pickup T, Sheth PB. Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection? *Arch Dermatol.* 2010; 146 (10):1151-1152.
20. Garavaglia MC, Altomare G. Etanercept therapy in patients with psoriasis and concomitant HCV infection. *Int J Immunopathol Pharmacol.* 2010;23(3):965-969.
21. Paradisi A, Caldarola G, Capizzi R et al. Safety of etanercept in patients with psoriasis and hepatitis C virus ossesse by liver histopathology: Preliminary data. *J Am Acad Dermatol.* 2010;62(6):1067-1069.
22. Mederacke I, Witte T, Wedemeyer H, et al. Successful clearance of hepatitis C virus with pegylated interferon α -2a, and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. *Ann Rheum Dis.* 2011;70(7):1343-1344.
23. Prignano F, Ricceri F, Pescitelli L, et al. Tumour necrosis factor- α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. *Br J Dermatol.* 2011;164(3):645-647.
24. Zanni M, Missale G, Santilli D, et al. Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients. *Eur J Dermatol.* 2011;21(4):564-567.
25. Collazo MH, González JR, Torres EA. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. *P R Health Sci J.* 2008;27(4):346-7.
26. Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. *Br J Dermatol.* 2013;168(3):609-16